Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

With PPLPHARMA's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 1.511000
forwardPE 38.709606
debtToEquity 69.519000
earningsGrowth 0.000000
revenueGrowth -0.001000
grossMargins 0.634850
operatingMargins 0.087990
trailingEps -2.470000
forwardEps 4.332000

PPLPHARMA's current ratio of 1.511 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that PPLPHARMA is financially well-prepared to meet its liabilities without difficulty.
PPLPHARMA's low growth in earnings and revenue indicates a potential decline in profits. This suggests that the company could be facing financial challenges, making it harder to sustain its current profit margins.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA

The price of Piramal Pharma Limited has consistently remained close to the lower end of price projections. This trend may reflect uncertainty in the market regarding the company's ability to deliver on growth expectations.

Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


Analysts' buy bias for PPLPHARMA signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to PPLPHARMA, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.